Caris Life Sciences, Inc.
Every calculator, already run for CAI
Open the full toolkit →You have the numbers on CAI. Get the argument.
A written report on which of these readings actually decide the outcome for Caris Life Sciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering CAIAnalyst Price Target Disagreement for Caris Life Sciences, Inc.
Wall Street's bull case implies +14% from the current price; the bear case implies -30%. A 44% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CAI
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect,…
CAI — frequently asked
Is CAI a buy right now?
Wall Street's consensus rating on Caris Life Sciences, Inc. is Buy across 14 analysts, with a mean price target of $28.15 (-11% vs. the current $31.65). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is CAI overvalued?
CAI trades at 3.3x trailing earnings, against a DCF fair value of $5 per share. The current price implies 32% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is CAI's next earnings date?
Caris Life Sciences, Inc. is next scheduled to report earnings around Nov 4, 2026. A full CAI research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Caris Life Sciences, Inc.?
Analysts covering Caris Life Sciences, Inc. (CAI) range from a bear-case target of $22.00 to a bull-case high of $36.00, with a mean consensus target of $28.15 across 13 analysts. The spread of $14.00 (44% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Caris Life Sciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Caris Life Sciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CAI research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Caris Life Sciences, Inc., in minutes. 3 free reports included with every account — no credit card required.